Svatantra.ai, Government Capital Intelligence Login / Sign Up
Platform Capabilities Life Science Intelligence Infrastructure Intelligence SEC Intelligence (coming soon) Defense Intelligence (coming soon) Critical Minerals Intelligence (coming soon) Energy Transition Capital (coming soon) Commodities Intelligence (coming soon) Methodology Calibration For Research Pricing FAQ About

Signal of the week · Research note · 4 Nov 2026

10 FDA warning letters dated 1 October 2026 target unapproved herpes and chlamydia products, 2 of them to Amazon and Walmart; five sweep days carry 144 of 585 drug and biologic warning letters since October 2024

Public FDA compliance records in Svatantra.ai's signal database show 22 warning letters from the agency's drug and biologic centers dated 1 to 23 October 2026. Twelve carry one date, 1 October 2026, and ten of those are a single sweep against unapproved over-the-counter products sold for herpes, chlamydia, gonorrhea and syphilis: eight to the firms behind the products and two to Amazon.com and Walmart for third-party listings shipped from their fulfillment warehouses. Across the whole table, five letter dates with ten or more letters account for 144 of 585 letters (24.6 percent, our arithmetic), while the median letter date carries one. This note sets out the counts, the ten letters, the earlier sweep days as public reporting describes them, and what the records do not show.

By Jayprakash Mistry, Founder, Svatantra.ai

One email with the PDF attached. You will be on the list for future notes and can unsubscribe from any of them. The list is not sold or shared.

Every number, and where it comes from

The first five figures in the note.

The full table has 17 rows. Each figure is as published on the date shown, with its denominator.

FigureWhat it measuresSource
22FDA warning letters from CDER and CBER with a letter date between 1 and 23 October 2026 (window searched 1 to 30 October): 22 distinct case IDs, 22 firms, 8 letter dates; 20 CDER, 2 CBER; 17 US, 5 foreign (China 2, Singapore, South Korea, Vietnam)Svatantra.ai signal database, count at 30 Oct 2026
12Warning letters dated 1 October 2026, 12 distinct case IDs, all CDER, all product type DrugsSvatantra.ai signal database, count at 30 Oct 2026
10Of the 12, letters in the STI sweep, matched by FDA case ID to the ten letters posted 6 October 2026 (case IDs 734781, 734784, 734925, 735070, 735147, 735272, 735346, 735464, 736006, 736557). The two others (Signature Formulations, LLC, 737964; Zhejiang Gaorong Cosmetic Co., Ltd, 732511) were not openedSvatantra.ai signal database, count at 30 Oct 2026; FDA warning letters, posted 6 Oct 2026
8 and 2Of the 10 sweep letters, 8 to firms that make or brand the products and 2 to marketplaces (Amazon.com, Inc.; Walmart, Inc.). Author's arithmetic on the ten letters openedFDA warning letters dated 1 Oct 2026
9 and 3Products named on Amazon's letter (FemiClear, HClear for him, HerpCare Ointment, HerpCare Spray, Herstat GST, Genital Herpes Ointment, RoyceDerm Herpes Relief Cream, Terragen HG Formula, Genital Herpes Intimate Wash) and on Walmart's (HClear for him, Herstat GST, Terragen HG Formula); products bought in July 2026FDA warning letters 736006 and 736557, dated 1 Oct 2026

12 more figures in the PDF, each with its source.

Sources

18 primary releases.

  1. US Food and Drug Administration, Center for Drug Evaluation and Research, Amazon.com, Inc., MARCS-CMS 736006 (1 October 2026 (posted 6 October 2026))
    Addressed to Andy Jassy, CEO. Nine products named: FemiClear, HClear for him, HerpCare Ointment, HerpCare Spray, Herstat GST, Genital Herpes Ointment, RoyceDerm Herpes Relief Cream, Terragen HG Formula, Genital Herpes Intimate Wash. "introduced or delivered for introduction into interstate commerce by Amazon via your Fulfillment by Amazon service"; "present a serious public health concern"; sections 301(d) and 505(a); "within fifteen (15) business days of receipt of this letter".
    fda.gov
  2. US Food and Drug Administration, Center for Drug Evaluation and Research, Walmart, Inc., MARCS-CMS 736557 (1 October 2026 (posted 6 October 2026))
    Addressed to John Furner, President and CEO. Products: HClear for him ("GENITAL HERPES SYMPTOMS"), Herstat GST ("Soothes and calms genital sores"), Terragen HG Formula ("relief of swelling and pain associated with genital sores."). "purchased on your website www.walmart.com in July 2026"; "introduced or delivered for introduction into interstate commerce by Walmart" "via your Walmart Fulfillment Services"; sections 301(d) and 505(a).
    fda.gov
  3. US Food and Drug Administration, Center for Drug Evaluation and Research, Bioactive Services USA, LLC / Herstat Inc., 734784 (1 October 2026 (posted 6 October 2026))
    Product "Herstat GST", labeled "Genital Sore Treatment" and "Effective for the treatment of genital sores"; sold on drsosnowski.com and herstat.com, reached from Facebook and Instagram; sections 301(d) and 505(a).
    fda.gov
  4. US Food and Drug Administration, Center for Drug Evaluation and Research, OrganiCare, LLC / OrganiCare Nature's Science, LLC, 734925 (1 October 2026 (posted 6 October 2026))
    Products "HClear for him" and "FemiClear Genital Herpes Symptoms"; claims include "kills 99.9% of the herpes simplex I & II viruses"; sold on femiclear.com, reached from Facebook and Instagram; sections 301(d) and 505(a).
    fda.gov
  5. US Food and Drug Administration, Center for Drug Evaluation and Research, DesBio/Deseret Biologicals, Inc., 735464 (1 October 2026 (posted 6 October 2026))
    Product "CHLA:10M" / "Chlamydia 10M", labeled homeopathic, "temporary relief of symptoms related to Chlamydia infection"; FDA states homeopathic labeling gives no exemption and the ingredient is not in the HPUS; sections 301(d) and 505(a).
    fda.gov
  6. US Food and Drug Administration, Center for Drug Evaluation and Research, Aidance Scientific, Inc., 735346 (1 October 2026 (posted 6 October 2026))
    Product "Terragen HG Formula", "Genital sores treatment, outbreak support"; sold on aidanceproducts.com and an Amazon storefront; sections 301(d) and 505(a).
    fda.gov
  7. US Food and Drug Administration, Center for Drug Evaluation and Research, Terramed, 735070 (1 October 2026 (posted 6 October 2026))
    Products "Genital Herpes Intimate Wash", "HerpCare Ointment", "HerpCare Spray", "HerpCare Genital Wart Remover Ointment"; sold on terramed.info; sections 201(g)(1), 201(p), 505(a), 301(d).
    fda.gov
  8. US Food and Drug Administration, Center for Drug Evaluation and Research, Graceful Touch, LLC, 735272 (1 October 2026 (posted 6 October 2026))
    Product "Herpes B Gone", formulated to "soothe herpes sores"; sold on gracefultouchproducts.org; sections 301(d) and 505(a).
    fda.gov
  9. US Food and Drug Administration, Center for Drug Evaluation and Research, The Platinum Healthcare LLC, 735147 (1 October 2026 (posted 6 October 2026))
    Products "Sycosis" and "Syphillinum", labeled for the "Gonorrhea miasm" and "Syphilis miasm" as an "Oral antigen"; sold on platinumwellnesscenter.org; homeopathic labeling no exemption; sections 301(d) and 505(a).
    fda.gov
  10. US Food and Drug Administration, Center for Drug Evaluation and Research, RoyceDerm LLC, 734781 (1 October 2026 (posted 6 October 2026))
    Product "Herpes Relief Cream", "specially formulated to help relieve the symptoms of Herpes" and "HELPS RELIEVE THE SYMPTOMS OF RASHES OR BLISTERS, ITCHY, REDNESS, AND PAIN."; sold on roycederm.com; sections 301(d) and 505(a).
    fda.gov
  11. US Food and Drug Administration, Warning Letters (table of posted letters) (Accessed 30 October 2026)
    Posting of 27 October 2026 includes three CDER letters dated 22 October 2026: "Northland Nuclear Medicine, LLC", "Sanrace Biotechnology Co., Ltd.", "TSP Solutions Pte. Ltd.", each "CGMP/Finished Pharmaceuticals/Adulterated". Used to check the October count against the public table.
    fda.gov
  12. Law360, FDA Accuses 10 Retailers Of Selling Unapproved STI Meds (6 October 2026)
    "accused Amazon, Walmart and other online retailers of selling unapproved drugs" "to treat herpes and other sexually transmitted infections". Paywalled after the first paragraph.
    law360.com
  13. Becker's Hospital Review, FDA flags patient safety risks from 9 unapproved drugs sold through Amazon (8 October 2026)
    "unapproved new drugs marketed to treat sexually transmitted infections or their symptoms"; "no OTC drug product has been approved for the treatment, cure, mitigation or prevention of any STI"; patients "may forgo timely medical care, increasing their risk of complications including infertility, sepsis and death"; "through its Fulfillment by Amazon service".
    beckershospitalreview.com
  14. Foreign Policy Journal, FDA Warning Letter Puts Walmart (NYSE: WMT) Marketplace Compliance Under Investor Scrutiny (14 October 2026)
    Secondary coverage of the Walmart letter: products bought on Walmart.com and fulfilled through Walmart Fulfillment Services; regulators "tied Walmart's responsibility to product offerings" including "third-party sellers". Does not quote the letter; used only as a recency check.
    foreignpolicyjournal.com
  15. Holland & Knight, FDA, HHS Taking Action Against Telehealth's Compounded Drug Advertising (29 September 2025)
    On 9 September 2025 FDA said it was "sending thousands of letters warning pharmaceutical companies to remove misleading ads", "issuing approximately 100 cease-and-desist letters to companies with deceptive ads", and "issued warning letters to telehealth providers and companies"; flagged claims such as "Weekly injectable GLP-1 with the same active ingredient as Ozempic and Wegovy".
    hklaw.com
  16. Fierce Healthcare, FDA ramps up crackdown on GLP-1 drug compounding with fresh batch of 30 warning letters (March 2026 (page undated; letters "sent Feb. 20 and made public March 3"))
    "fresh batch of 30 warning letters" to telehealth companies for "false or misleading" claims about compounded semaglutide and tirzepatide; FDA reviewed the websites in December 2025; letters state "Compounded drug products are not FDA-approved" and "Your claims imply that your products have been FDA-approved".
    fiercehealthcare.com
  17. Epstein Becker Green, Health Law Advisor, At the Half: No Free Kicks in FDA's 2026 Enforcement (30 June 2026)
    CDER "had issued an additional 30 warning letters" on compounded GLP-1 claims and "a third tranche of 25 letters followed in mid-June 2026"; "FDA issued 12 letters to companies (including a major online marketplace)" on prostate, erectile dysfunction and urinary claims; CDER "the most active FDA center of the year to date".
    ebglaw.com
  18. Svatantra.ai, Signal database (30 October 2026)
    Counted: FDA compliance-action records of type Warning Letter from the drug center (CDER) and biologics center (CBER), by letter date, counted once per FDA case ID. October 2026 window 1 to 30 October: 22 letters (dated 1 to 23 October), 12 of them dated 1 October, 10 of those matched by case ID to FDA's posted STI letters. Full table 29 October 2024 to 23 October 2026: 585 letters on 262 letter dates; five dates with 10 or more letters (9 Sep 2025, 20 Feb 2026, 8 Jun 2026, 17 Jun 2026, 1 Oct 2026) carry 144. Amazon 4 letters, Walmart 1. Counts at 30 October 2026.
    svatantra.ai